title: A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.
authors.forename: Peter
authors.initials: P
authors.lastname: Mollee
authors.forename: Campbell
authors.initials: C
authors.lastname: Tiley
authors.forename: Ilona
authors.initials: I
authors.lastname: Cunningham
authors.forename: John
authors.initials: J
authors.lastname: Moore
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Paul
authors.initials: P
authors.lastname: Cannell
authors.forename: Steve
authors.initials: S
authors.lastname: Gibbons
authors.forename: Jill
authors.initials: J
authors.lastname: Tate
authors.forename: Sanjoy
authors.initials: S
authors.lastname: Paul
authors.forename: Helen
authors.initials: H
authors.lastname: Mar Fan
authors.forename: Devinder S
authors.initials: DS
authors.lastname: Gill
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000401:mortality; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan